헬리코박터 파일로리 제균 치료로 감소시킬 수 있는 것: 위 밖의 변화
Benefits of Helicobacter pylori Eradication on Extragastric Diseases
김태준, 이혁,
소속 상세정보
김태준 ( Kim Tae-Jun )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
이혁 ( Lee Hyuk )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
Abstract
Helicobacter pylori (H. pylori) eradication can reduce the risk of gastric diseases such as gastritis, gastric ulcer, and gastric adenocarcinoma. Since H. pylori was discovered more than 30 years ago, many studies have reported associations between H. pylori infection and extragastric diseases such as immune thrombocytopenia and iron-deficiency anemia. Thus, recent guidelines recommended H. pylori eradication in patients with those diseases. In contrast, although the role of H. pylori eradication in other extragastric diseases remains controversial, there is growing evidence of its benefit on them, especially cardiovascular (ischemic heart disease and stroke), metabolic (dyslipidemia, diabetes mellitus, and non-alcoholic fatty liver disease), neurodegenerative (Parkinson’s disease and Alzheimer’s disease), autoimmune (Graves’ disease, Hashimoto’s thyroiditis, Raynaud’s syndrome, rosacea, and chronic urticaria), and other (cap polyposis, colorectal mucosa-associated lymphoid tissue lymphoma, periodontal disease, hyperemesis gravidarum, and osteoporosis) conditions. A recent prospective randomized study reported that H. pylori eradication improved insulin resistance and dyslipidemia. These findings were consistent with the results of a recent meta-analysis. Therefore, well-designed prospective interventional studies are needed to examine the effects of H. pylori eradication on various extragastric diseases.
키워드
Eradication; Extragastric diseases; Helicobacter pylori
원문 및 링크아웃 정보
등재저널 정보